Pediatric Drugs

, Volume 5, Issue 12, pp 795–801 | Cite as

Refractory Idiopathic Immune Thrombocytopenic Purpura in Children

Current and Future Treatment Options
Therapy In Practice

Abstract

A minority of children with idiopathic or immune thrombocytopenic purpura (ITP) have the refractory chronic form with bleeding problems (stage III or IV). The aim of this article is to provide an update on the immunopathogenesis and management of children with bleeding and severe refractory ITP. The management of such patients, according to a staging guideline, is described.

Recent clinical and laboratory observations document the disturbed immune responses that occur on various levels in chronic ITP. New therapeutic options are directed towards influencing these immunopathogenic mechanisms.

Because ITP is not adequately defined and has heterogeneous manifestations, today’s management recommendations are largely opinion-based rather than evidence-based. In severe refractory childhood ITP, consensus between the treating physician and the patient has to be achieved on an individual basis. The aim is to maintain the disease at stages I or II, with minimal intervention, and to prevent bleeding. If bleeding is not under control, medical treatment (as described in this article), or splenectomy, has to be considered.

Although there is a paucity of data relating to children, potential new treatment options for refractory ITP include strategies aimed at influencing antigenemia, the T cell immune response (e.g. cyclosporine, CTLA-4-Ig) or the B-cell immune response (e.g. anti-CD20 monoclonal antibody, anti-CD52 monoclonal antibody, interferon).

New prospective, cooperative ITP registries have been created to search for subgroups with different severities of ITP, which will be the selection criteria of future controlled studies in pediatric patients with refractory ITP.

References

  1. 1.
    Imbach P. Immune thrombocytopenic purpura. In: Lilleyman JS, Hann IM, Blanchette VS, editors. Pediatric hematology. 2nd ed. London: Churchill Livingstone, 1999Google Scholar
  2. 2.
    Lilleymann JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999; 71: 251–3Google Scholar
  3. 3.
    Kühne T, Imbach P, Bolton-Maggs PHB, et al., for the Intercontinental Childhood FTP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001; 358: 2122–5PubMedCrossRefGoogle Scholar
  4. 4.
    Imbach P, Akatsuka J, Blanchette V, et al. Immunothrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 1995; 154(3): 60–4CrossRefGoogle Scholar
  5. 5.
    Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433–69PubMedGoogle Scholar
  6. 6.
    Imbach P, Barandun S, D’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; I: 1228–31CrossRefGoogle Scholar
  7. 7.
    Salama A, Kiefel V, Amberg R, et al. Treatment of autoimmune thrombocytopenic purpura with Rhesus antibodies (anti Rho[D]). Blut 1984; 49: 29–35PubMedCrossRefGoogle Scholar
  8. 8.
    Imbach P, Kühne T, Holländer G. Immunologic aspects in pathogenesis and treatment of immune thrombocytopenic purpura (ITP) in children. Curr Opin Pediatr 1997; 9: 35–40PubMedCrossRefGoogle Scholar
  9. 9.
    Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9–12PubMedCrossRefGoogle Scholar
  10. 10.
    Coopamah MD, Garvey MB, Freedman J, et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003; 17: 69–80PubMedCrossRefGoogle Scholar
  11. 11.
    Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002; 100: 1774–9PubMedGoogle Scholar
  12. 12.
    Trotter JL. Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of bursts and effects of cyclosporine. J Neuroimmunol 1990; 28(1): 9–14PubMedCrossRefGoogle Scholar
  13. 13.
    Tebib JG, Boughaba H, Letroublon MC. Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression. Eur Cytokine Netw 1991; 2: 239–43PubMedGoogle Scholar
  14. 14.
    Huang Y-P, Perrin LH, Miescher PA, et al. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1991; 141: 827–33Google Scholar
  15. 15.
    DeFrance T, Vanbervliet B, Briere F, et al. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin. A J Exp Med 1992; 175: 671–82CrossRefGoogle Scholar
  16. 16.
    Howard M, Muchamuel T, Audrade S, et al. Anti-inflammatory effect of IL-10. J Exp Med 1993; 177: 1205–8PubMedCrossRefGoogle Scholar
  17. 17.
    Nepom G, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991; 9: 493–525PubMedCrossRefGoogle Scholar
  18. 18.
    George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88(1): 3–40PubMedGoogle Scholar
  19. 19.
    British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574–96CrossRefGoogle Scholar
  20. 20.
    Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309–17PubMedGoogle Scholar
  21. 21.
    Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008PubMedCrossRefGoogle Scholar
  22. 22.
    Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330: 1560–4PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshida K, Yamazaki Y, Mizuno R, et al. Laparoscopic splenectomy in children: preliminary result and comparison with the open technique. Surg Endose 1995; 9: 1279–82CrossRefGoogle Scholar
  24. 24.
    Cahill MR, Macey MG, Cavenagh JD, et al. Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol 1998; 100: 358–64PubMedCrossRefGoogle Scholar
  25. 25.
    Snyder HW, Cochran SK, Balint JP, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79: 2237–45PubMedGoogle Scholar
  26. 26.
    Meeker ND, Goldsby R, Terrill KR, et al. Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25: 173–5PubMedCrossRefGoogle Scholar
  27. 27.
    Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori [letter]. Lancet 1998; 352: 878PubMedCrossRefGoogle Scholar
  28. 28.
    Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97: 812–4PubMedCrossRefGoogle Scholar
  29. 29.
    Ellaurie M, Burns E, Bernstein L, et al. Thrombocytopenia and human immunodeficiency virus in children. Pediatrics 1988; 82: 905–8PubMedGoogle Scholar
  30. 30.
    Imbach P, Luginbühl L, Späth P, et al. Cyclosporin A (CyA) and intravenous immunoglobulin (i.v. IgG) in chronic immune thrombocytopenic purpura (ITP) in childhood: a clinical and immunological study (progress report). In: Schindler R, editor. Cyclosporin in autoimmune disease. Berlin: Springer Verlag, 1985: 268–9CrossRefGoogle Scholar
  31. 31.
    Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 2001; 114: 121–5PubMedCrossRefGoogle Scholar
  32. 32.
    Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99: 1482–5PubMedCrossRefGoogle Scholar
  33. 33.
    Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243–52PubMedCrossRefGoogle Scholar
  34. 34.
    Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45PubMedGoogle Scholar
  35. 35.
    Stasi R, Pagana A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952–7PubMedCrossRefGoogle Scholar
  36. 36.
    Cooper N, Stasi R, Feuerstein M, et al. Transient B cell depletion with rituximab, an anti CD20 monoclonal antibody, resulted in lasting complete responses in 16 of 57 adults with refractory immune thrombocytopenic purpura [abstract no. 187]. American Society of Hematology 44th Annual Meeting; 2002 Dec 6–10; PhiladelphiaGoogle Scholar
  37. 37.
    Giagounidis AAN, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69: 95–100PubMedCrossRefGoogle Scholar
  38. 38.
    Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189–95PubMedGoogle Scholar
  39. 39.
    Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 6Suppl. 12: 99–103Google Scholar
  40. 40.
    Delgado J. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002; 87: 215–6PubMedGoogle Scholar
  41. 41.
    Monroy RH, Viveros PV, Violante MR. Effect of anti-CD20 (rituximab) in refractory immune thrombocytopenic purpura (RITP): report of three new cases [abstract no. 3797]. American Society of Hematology 44th Annual Meeting; 2002 Dec 6–10; PhiladelphiaGoogle Scholar
  42. 42.
    Rosenthal E, Karsenti JM, Pesce A, et al. Anti-CD20 monoclonal antibody (rituximab) administration in patients with refractory immunologic thrombocytopenic purpura [abstract no. 2194]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7–11; OrlandoGoogle Scholar
  43. 43.
    Schuler US, Florek M, Mueller J, et al. Successful rituximab treatment of immune thrombocytopenia (FTP) in an elderly lady with systemic mastocytosis [abstract no. 3875]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7–11; OrlandoGoogle Scholar
  44. 44.
    Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia: case report. Eur J Haematol 2001; 66: 408–11PubMedCrossRefGoogle Scholar
  45. 45.
    Shvidel L, Klepfish A, Berrebi A. Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-hodgkin’s lymphoma. Am J Hematol 2001; 67: 213–9PubMedCrossRefGoogle Scholar
  46. 46.
    Patel K, Berman J, Ferber A, et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001; 67: 59–60PubMedCrossRefGoogle Scholar
  47. 47.
    Hedge UP, Wilson WH, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100(6): 2260–2Google Scholar
  48. 48.
    Heelan BT, Tormey V, Amlot P, et al. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002; 118: 1078–81PubMedCrossRefGoogle Scholar
  49. 49.
    Gilleece MH, Dexter TM. Effect of compath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–12PubMedGoogle Scholar
  50. 50.
    Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1995; 1: 175–87PubMedCrossRefGoogle Scholar
  51. 51.
    Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990; 323: 250–4PubMedCrossRefGoogle Scholar
  52. 52.
    Lockwood CM. Refractory Wegener’s granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998; 32: 473–8PubMedGoogle Scholar
  53. 53.
    Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Compath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–8PubMedCrossRefGoogle Scholar
  54. 54.
    Proctor SJ, Jackson G, Carey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Blood 1989; 74: 1894–7PubMedGoogle Scholar
  55. 55.
    Hrstkova H, Bajer M, Michalek J. Recombinant human interferon alpha-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2002; 24: 299–303PubMedCrossRefGoogle Scholar
  56. 56.
    Rice L, Nichol JL, McMillan R. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Haematol 2001; 68: 210–4CrossRefGoogle Scholar
  57. 57.
    Huhn RD, Read EJ, Rick M, et al. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia [abstract]. Blood 1999; 94: 178Google Scholar
  58. 58.
    ICIS Intercontinental Childhood ITP Study Group [online]. Available from URL: http://www.unibas.ch/itpbasel [Accessed 2003 Oct 29]

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Oncology/HematologyUniversity Children’s Hospital (UKBB)BaselSwitzerland

Personalised recommendations